Highest-materiality recent filing
ASPAC II issues $500K promissory note to sponsor; director Chan resigns
Issued $500,000 unsecured promissory note to sponsor A SPAC II (Holdings) Corp on October 17, 2025.
SPAC II Acquisition dismisses Marcum Asia, appoints FundCertify as new auditor
Audit committee approved dismissal of Marcum Asia and engagement of FundCertify on Aug 5, 2025.
ASCB shareholders approve 24-month extension and China target amendment; 344K shares redeemed
Shareholders approved extension of business combination deadline from Aug 5, 2025 to Aug 5, 2027.
ASPAC II Acquisition Corp. replaces majority of board and top executives effective July 28, 2025
Four directors (MacLean, Chan, Biniak, Cummins) resigned; replaced by Yip Tsz Yan, Tsang Wing Sze, Luk Sui Cheung Peter, Minjie Mao.
ASPAC II Acquisition Corp. issues $152K promissory note to sponsor for working capital
Issued unsecured promissory note for $152,000 to sponsor A SPAC II (Holdings) Corp. on July 14, 2025.
ASPAC II Acquisition Corp. issues $160K promissory note to sponsor for working capital
$160,000 unsecured promissory note issued to sponsor A SPAC II (Holdings) Corp.
ASPAC II receives Nasdaq delisting notice for failing minimum shareholder rule
Nasdaq notified on Sep 13, 2024 that ASPAC II did not meet minimum 400 total shareholders requirement (Rule 5450(a)(2)).
ASCB shareholders approve extension to August 2025; ~1.6M shares redeemed
Extension Amendment Proposal approved at EGM on July 23, 2024: deadline extended from August 5, 2024 to August 5, 2025.
ASPAC II identifies two potential SPAC targets: Vietnam biofuel and Nepal copper mining
Entered non-binding LOIs with a Vietnam biofuel target and a Nepal copper mining target; no minimum cash condition.
ASPAC II receives Nasdaq deficiency letter for insufficient public holders
Received Nasdaq letter on March 15, 2024 for failing to maintain minimum 400 public holders (Rule 5450(a)(2)).
Received Nasdaq notice on Dec 11, 2023 for failing $50M market value of listed securities over 30 consecutive business days.
ASCB shareholders approve extension to August 5, 2024; 18M shares redeemed
Extension Amendment Proposal passed with 14,211,081 votes for and 7,884,094 against.
A SPAC II identifies Taiwan medtech target for potential business combination
Target specializes in microsphere tech for ultrasound contrast agents and drug delivery.
A SPAC II Acquisition Corp. names Serena Shie CEO; Tsang resigns as CEO, stays CFO
Claudius Tsang resigned as CEO on Aug 29, 2022; not due to any disagreement with the Company.
Ordinary shares (ASCB), warrants (ASCBW), and rights (ASCBR) begin separate trading on Nasdaq as of May 31, 2022.
IPO of 20,000,000 units at $10.00 each generated gross proceeds of $200,000,000.
SPAC II Acquisition Corp. closes IPO of 20M units, raises $200M gross; private placement adds $8.97M
IPO of 20,000,000 units at $10.00/unit for gross proceeds of $200,000,000.
On August 29, 2022, A SPAC II Acquisition Corp. (the “Company”) received the resignation of Mr. Claudius Tsang (“Mr. Tsang”) as Chief Executive Officer of the Company.
On the same date, Ms. Serena Shie (“Ms. Shie”) was appointed as the Company’s Chief Executive Officer by the Company’s board of directors.
Max materiality 0.85 · Median 0.60 · Most common event other_material